BiosyentBIOYF +4.06%98 EV-to-FCF is 12.75 as of Jun. 30, 2026, which is 23% below its 10-year median of 16.61. GuruFocus rates BIOYF with a GF Score™ of 98/100 and a GF Value™ of $11.31 (Fairly Valued). The stock has 2 warning signs investors should review. Among 559 Drug Manufacturers companies, Biosyent ranks better than 67.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biosyent's Enterprise Value is $112.40 Mil.
Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $8.82 Mil. Therefore, Biosyent's EV-to-FCF for today is 12.75.
The historical rank and industry rank for Biosyent's EV-to-FCF or its related term are showing as below:
BIOYF'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.85 Med: 16.61 Max: 64.65
Current: 12.75
During the past 13 years, the highest EV-to-FCF of Biosyent was 64.65. The lowest was 6.85. And the median was 16.61.
BIOYF's EV-to-FCF is ranked better than 67.8% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs BIOYF: 12.75
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biosyent's share price for today is $10.26.
Biosyent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.572.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biosyent EV-to-FCF Related Terms
Biosyent EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biosyent's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biosyent's EV-to-FCF falls into.
Biosyent's current Enterprise Value is $112.40 Mil.
Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (BIOYF) has a EV-to-FCF of 12.75 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosyent and its competitors. This is 23% below median its historical median of 16.61. Over the past decade, Biosyent's EV-to-FCF has ranged from 6.85 to 64.65. According to the industry distribution chart, Biosyent ranks #180 out of 559 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Biosyent's EV-to-FCF too high?
Biosyent's current EV-to-FCF of 12.75 is 23% below median its 10-year median of 16.61. Over the past 10 years, this metric has ranged from a low of 6.85 to a high of 64.65. The Drug Manufacturers industry median EV-to-FCF is 20.02. Biosyent's value of 12.75 is 36.3% below this industry median. Based on the distribution chart, Biosyent ranks #180 out of 559 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biosyent has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #180 out of 559 companies for EV-to-FCF. This puts Biosyent in the upper half of its industry. The industry median EV-to-FCF is 20.02. Biosyent's value of 12.75 is 36.3% below this benchmark. Historically, Biosyent's own EV-to-FCF has ranged from 6.85 to 64.65 over the past decade. While the company's 10-year median is 16.61 vs. the industry median of 20.02, Biosyent has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current EV-to-FCF of 12.75 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current EV-to-FCF is 12.75, which is 23% below median its own 10-year median of 16.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (BIOYF) is currently considered Fairly Valued. The stock's GF Value™ is $11.31, compared to a current price of $10.26 — trading 9.3% below its estimated fair value. The current EV-to-FCF is 12.75, which is 23% below median its 10-year median of 16.61 and 36.3% below the Drug Manufacturers industry median of 20.02. Biosyent's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biosyent (BIOYF), the current EV-to-FCF is 12.75 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (BIOYF) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of $10.26 is trading 9.3% below its estimated GF Value™ of $11.31.
GuruFocus considers Biosyent to be Fairly Valued.
Key valuation signals for BIOYF:
EV-to-FCF: 12.75 (23% below median its 10-year median of 16.61)
GF Value™: $11.31 vs. price of $10.26 (9.3% below fair value)
Industry Position: 36.3% below the Drug Manufacturers median (#180 of 559)
No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score
Get the complete analysis for BIOYF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOYF has been successfully added to your 
